Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1991-4-3
|
| pubmed:abstractText |
The incidence of major valve-related complications was evaluated in a series of patients in whom the Hancock pericardial xenograft was used for aortic (AVR; n = 84), mitral (MVR; n = 17) and mitral-aortic (MAVR; n = 13) valve replacement. At 7 years actuarial survival is 66% +/- 8% after AVR, 64% +/- 13% after MVR, and 41% +/- 15% after MAVR, whereas actuarial freedom from valve-related death is 79% +/- 7% after AVR, 78% +/- 13% after MVR, and 81% +/- 12% after MAVR. Actuarial freedom from thromboemboli and anticoagulant-related hemorrhage at 7 years is 93% +/- 4% and 98% +/- 2% after AVR and 83% +/- 10% and 88% +/- 11% after MVR; no such complications occurred after MAVR. Structural valve deterioration determined at reoperation, at autopsy, or by clinical investigation was observed in 34 patients with AVR (10.0 +/- 0.2%/patient-year), in 10 with MVR (10.6 +/- 3.3%/patient-year), and in 9 with MAVR (16.6 +/- 5.5%/patient-year). After AVR, 19 patients underwent reoperation and 2 died before reoperation; 4 patients with MVR underwent reoperation, and 7 patients with MAVR underwent reoperation and 1 died before reoperation. Seventy-eight percent of the current survivors (13 patients with AVR, 7 with MVR, and 1 with MAVR) have clinical evidence of valve failure. At 7 years actuarial freedom from structural deterioration of the Hancock pericardial xenograft is 25% +/- 7% after AVR, 29% +/- 14% after MVR, and 0% after MAVR.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0003-4975
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
51
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
430-7
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:1998420-Adult,
pubmed-meshheading:1998420-Aged,
pubmed-meshheading:1998420-Anticoagulants,
pubmed-meshheading:1998420-Aortic Valve,
pubmed-meshheading:1998420-Bioprosthesis,
pubmed-meshheading:1998420-Endocarditis,
pubmed-meshheading:1998420-Female,
pubmed-meshheading:1998420-Follow-Up Studies,
pubmed-meshheading:1998420-Heart Valve Prosthesis,
pubmed-meshheading:1998420-Hemorrhage,
pubmed-meshheading:1998420-Humans,
pubmed-meshheading:1998420-Male,
pubmed-meshheading:1998420-Middle Aged,
pubmed-meshheading:1998420-Mitral Valve,
pubmed-meshheading:1998420-Prosthesis Failure,
pubmed-meshheading:1998420-Reoperation,
pubmed-meshheading:1998420-Survival Rate,
pubmed-meshheading:1998420-Thromboembolism
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Failure of Hancock pericardial xenografts: is prophylactic bioprosthetic replacement justified?
|
| pubmed:affiliation |
Department of Cardiovascular Surgery, University of Padova Medical School, Italy.
|
| pubmed:publicationType |
Journal Article
|